Document:

Seventh Amendment to Patent License Agreement

 Exhibit 10.20 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been
redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission. 
 SEVENTH AMENDMENT TO PATENT LICENSE AGREEMENT 
 THIS SEVENTH AMENDMENT
TO PATENT LICENSE AGREEMENT (the “Amendment”) is made and entered into effective as of October 27, 2006 (the “Amendment Effective Date”), by and between Massachusetts Institute of Technology, a
Massachusetts corporation (“M.I.T.”), and Sangamo BioSciences, Inc., a Delaware corporation (“Sangamo”) having principal offices at 501 Canal Blvd, Suite A100, Richmond, CA 94804. 
 M.I.T. and Sangamo hereby agree to amend that certain Patent License Agreement, dated May 9, 1996, as previously amended (the
“Agreement”) as follows: 
 1. Definitions. All defined terms used and not otherwise defined in this Amendment have the
meanings ascribed to such terms in the Agreement. For the purpose of this Amendment, the following terms, when capitalized, have the following meanings: 
 (a) “Downstream Product” means any product discovered or developed by a Sublicensee through the use solely in the Reagent Field of Licensed Product(s) or Licensed Process(es) for which no
payment was made by Sangamo pursuant to Section 3(a) or 3(b). 
 (b) “Reagent Field” means the use of zinc
finger proteins as non-therapeutic reagents to modify the genome or nucleic acid or protein expression of a cell. The Reagents Field shall exclude the Agricultural Field. 
 (c) “Reagent Product” means (i) any Licensed Product in the Reagent Field or (ii) any Licensed Process in the Reagent Field. 
 (d) “Reagent Sublicense Income” means (i) any running royalty received by Sangamo from a Sublicensee based on such
Sublicensee’s sales of a Downstream Product and (ii) any milestone payments received by Sangamo from a Sublicensee as result of such Sublicensee achieving development or commercialization milestones, in each case with respect to a
Downstream Product. For clarity, Reagent Sublicense Income shall not include any upfront payments or research funding received by Sangamo, any payments for Sangamo equity, or payments received by Sangamo as result of the achievement of technical
milestones with respect to a Reagent Product. 
 2. Field. For clarity, the Fields of Use shall include the Reagent Field. 
 3. Financial Terms. Notwithstanding the terms and conditions of the Agreement (including without limitation Article 4 thereof), Sangamo’s sole
financial obligation to M.I.T. with respect to (x) the grant of sublicenses under the Patent Rights in the Reagent Field to Sublicensees and (y) the exploitation of the Patent Rights in the Reagent Field by Sangamo and/or Sublicensees,
including the development and commercialization of Reagent Products and the development and commercialization of Downstream Products, shall be as follows: 

 (a) Sangamo shall pay M.I.T. [***] percent ([***]%) of Net Sales of
Reagent Products sold directly by Sangamo (which Net Sales shall be based solely on Sangamo’s billings). 
 (b)
Sangamo shall pay M.I.T. [***] percent ([***]%) of any amounts received by Sangamo as a result of the sale of Reagent Products by a third party. 
 (c) Sangamo shall pay M.I.T. [***] percent ([***]%) of all Reagent Sublicense Income received by Sangamo from Sublicensees. Such payments shall be due sixty (60) days after the
end of the quarter in which Sangamo receives such Reagent Sublicense Income and shall accompany the report contemplated by Section 5.2 of the Agreement. 
 4. Miscellaneous. This Amendment amends the terms of Agreement as expressly provided above, and the Agreement, as so amended and including all of its other terms and provisions that are not
amended, remains in full force and effect. This Amendment may be executed in counterparts and by facsimile. 
  

 2 
  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 IN WITNESS WHEREOF, the parties hereto have caused this Seventh Amendment to Patent
License Agreement to be executed by their duly authorized representatives as of the date first above written. 
  

			
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY
		
	By:	 	 /s/ Lita Nelsen

		
	Name:	 	 Lita L. Nelsen

		
	Title:	 	 Director, Technology Licensing Office

	
	SANGAMO BIOSCIENCES, INC.
		
	By:	 	 /s/ Edward Lanphier

		
	Name:	 	 Edward Lanphier

		
	Title:	 	 President & CEO

  

 3First Amendment of Research and Commercial Option License Agreement

 Exhibit 10.21 
 FIRST AMENDMENT OF THE 
 RESEARCH AND COMMERCIAL
LICENSE OPTION AGREEMENT 
 The Parties to the Research and Commercial License Option Agreement of October 1, 2005
(“Agreement”), SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100,
Richmond, California 94804 (“Sangamo”), and DOW AGROSCIENCES LLC, a Delaware limited liability company having its principal place of business at 9330 Zionsville Road. Indianapolis,
Indiana 46268 (“DAS”), hereby amend the Agreement as follows: 
 A. Section 1.50 is amended to read: 
 1.50 “Product Specific Invention” means an invention, whether patentable or not, that (a) is made by (i) Sangamo
in carrying out the Research Program or Manufacturing ZFP Products for DAS or Sublicensees pursuant to Section 7.1 or (ii) DAS or its Affiliates or Sublicensees under this Agreement and (b) is specific to (i) a ZFP Product that
is directed to a particular DNA sequence in a plant and solely useful for modifying the sequence or expression of a gene in such plant related to such DNA sequence, or (ii) the modified form of such DNA sequence (or the modified protein encoded
by such modified DNA sequence) as found in the resulting Licensed Product, or (iii) the native form of the DNA sequence of Material provided by DAS pursuant to Section 10.8 or the protein encoded by such native DNA sequence. 
 B. The following Section 10.8 is added: 
 10.8 Exchange of Material for the Research Program 
 (a) Each Party may,
from time to time, wish to supply to the other Party proprietary biological or chemical material and nucleic acid sequences (“Material”) under the terms and conditions of this Agreement for use in the Research Program. The supply of
Material on or after the Amendment Execution Date (as defined below) shall be promptly confirmed by a writing describing the Material and the date of its exchange in the form of Exhibit G (attached hereto). Exhibit H lists all Materials exchanged
prior to the Amendment Execution Date and the date of such exchange. 
 (b) For each supply of Material (other than ZFP Products
supplied by Sangamo to DAS), the supplying Party grants to the receiving Party a non-exclusive right to use such Material for the sole purpose of work on the Research Program. DAS’ rights with respect to ZFP Products shall be as set forth in
Article 2. 
  

 1 

 (c) Each Party shall only supply Material under this Section 10.8 that is the sole
property or under the control of such Party. Each Party recognizes that no license is granted or implied to such Party with respect to the Material supplied by the other Party under this Section 10.8 unless otherwise provided in this Agreement.

 (d) Except as authorized for the Research Program, the receiving Party shall not modify Material, nor have Material modified,
shall not conduct any mode of action studies on Material, shall not reverse engineer Material, and shall use reasonable efforts to protect Material from access by Third Parties other than its employees or consultants who are obligated to hold
Material in confidence. At the supplying Party’s option, the receiving Party shall either return to the supplying Party or destroy all remaining Material upon the earlier of completion of the Research Program or the supplying Party’s
written request. The receiving Party shall not, without the written permission of the supplying Party, use the Material supplied hereunder as the basis for an application for a patent or other form of protection or registration covering the Material
or its use. 
 C. Except as amended hereby, the Agreement shall remain in full force and effect. Those amendments made herein shall be effective
retroactive to October 1, 2005. 
 IN WITNESS WHEREOF,
the Parties have executed this First Amendment of the Research and Commercial License Option Agreement in duplicate originals by their proper officers as of August     , 2006 (the “Amendment Execution Date”).

  

									
	SANGAMO BIOSCIENCES, INC.	 		 	DOW AGROSCIENCES LLC
					
	By:	 	 /s/ David G. Ichikawa
	 		 	By:	 	 /s/ William A. Kleschick

	Name:	 	 David G. Ichikawa
	 		 	Name:	 	 William A. Kleschick, Ph.D.

	Title:	 	 SVP Business Development
	 		 	Title:	 	 Global Leader Discovery Research
 November 7, 2006

  

 2 

 Exhibit G 
 Material Transmittal Form 
 Pursuant to Article 10.8 of the Research
and Commercial License Option Agreement 
 Name of DAS representative providing Material
(print):                                       
                                         
                                       
 Signature of such DAS
representative:                                      
                                         
                                         
                           
 Date that Material is provided to
Sangamo:                                       
                                         
                                         
                  
 Project
reference:                                       
                                         
                                         
                                         
                  
 DESCRIPTION OF MATERIAL:

  

 3 

 Exhibit H 
 Transferred Materials 
  

							
	 Name of the
 person supplying
 the material
	    	 Date material
 transferred to
 Sangamo
	    	 Project
reference
	    	 Description of material

				
	Stephen Novak/ Manju Gupta	    	4-Mar-06	    	EPSPS project	    	Nucleic acid sequences of four EPSPS paralogs for designing ZFNs
				
	Stephen Novak/ Manju Gupta	    	18-May-06	    	EPSPS project	    	Clones of EPSPS paralogs for creating reporter lines in 293 kidney cells
				
	Stephen Novak/ Manju Gupta	    	16-May-06	    	No sat canola	    	Total genomic DNA (100 ug) of canola Nexera 710 variety
				
	Stephen Novak/ Manju Gupta	    	 14-Aug-06
  
	    	 No sat canola
  
	    	Total RNA extracted from canola Nex710 immature seeds 5, 10, 15 and 20 day after flowering (DAF). Total RNA were either treated or un-treated with DNasel for RACE (random
amplification of cDNA ends) analysis to determine the length of 5’ untranslated regions (UTR)
				
	Stephen Novak/ Manju Gupta	    	16-Aug-06	    	No sat canola	    	1) ~ 1 g Immature green seeds of Nex710 from 10 DAF 2) 10-15 g leaves (shipped in dry ice) of Nex710 for nuclei isolation toward determining DNasel hypersensitive sites for ZFP-TF
designs

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]